BioCardia, Inc. has announced its participation in the upcoming Heart Failure Society of America (HFSA) Annual Scientific Meeting, where it will present the design of its CardiAMP HF II Trial. This event, taking place from October 9 to 12, 2026, in Phoenix, Arizona, is significant as it underscores BioCardia's commitment to advancing cellular therapies for heart failure.
The CardiAMP HF II Trial aims to evaluate the efficacy of high-dose autologous cell treatment for patients with ischemic heart failure of reduced ejection fraction (HFrEF) who are already on guideline-directed medical therapy. This presentation will provide insights into the study's design and the scientific rationale behind it.
BioCardia's announcement is crucial not only for the company but also for the broader biological products industry, which is increasingly focused on innovative therapies for cardiovascular conditions. The trial's focus on minimally invasive autologous cell therapy could set new standards in treatment approaches, potentially influencing competitors in the biological products sector.
According to the filing, the company has received a category B designation from the FDA for its CardiAMP cell therapy system, indicating that the device's safety and effectiveness have been sufficiently established. The ongoing CardiAMP HF II trial is expected to support further FDA approval.
Peter Altman, PhD, BioCardia's President and CEO, expressed optimism about the trial and the company's ongoing regulatory submissions with the FDA and Japan's PMDA. He stated, “We are advancing the confirmatory CardiAMP HF II trial with world-class centers. At the HFSA Annual Scientific meeting, we have scheduled meetings with leaders in heart failure care to discuss the evidence supporting this therapy.”
BioCardia, based in Sunnyvale, California, is recognized as a leader in cellular and cell-derived therapeutics aimed at treating cardiovascular and pulmonary diseases. The company’s innovative platforms, including CardiAMP and CardiALLO™ therapies, are at the forefront of its research and development efforts.
The filing, dated October 7, 2026, indicates that a copy of the press release detailing this announcement is attached as Exhibit 99.1. The strategic focus on presenting at the HFSA meeting may enhance BioCardia's visibility and foster collaborations within the medical community.
Looking ahead, BioCardia's next steps will likely involve ongoing discussions with healthcare leaders and potential collaborations, although the filing does not specify any immediate actions following the presentation.